Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Vaccines: 10th Anniversary
share announcement

Vaccines: 10th Anniversary

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 36946

Special Issue Editors

Dr. Fernando Ferreira

E-Mail Website
Guest Editor
Faculty of Veterinary Medicine, University of Lisbon, Avenida da Universidade Técnica, 1300-477 Lisboa, Portugal
Interests: veterinary oncology; veterinary virology; cellular and molecular biology; oncogenic mechanisms; molecular oncology; chromatin remodeling; cell-virus interactions; vaccines and cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Amy Rasley

E-Mail Website
Guest Editor
Lawrence Livermore National Laboratory, 7000 East Ave, Livermore, CA 94550, USA
Interests: vaccines; nanoparticles; innate immunity; infectious diseases
Dr. Domenico Mattoscio

E-Mail Website
Guest Editor
Center for Advanced Studies and Technology, Department of Medical, Oral and Biotechnology Science, “G. d’Annunzio” University of Chieti – Pescara, Chieti, Italy
Interests: inflammation; resolution; resolvins; lipoxins; oncoviruses; hpv; autophagy; neutrophils; macrophages; cystic fibrosis; chronic inflammation
Special Issues, Collections and Topics in MDPI journals
Dr. Laura Pellegrinelli

E-Mail Website
Guest Editor
Department of Biomedical of Health, University of Milan, 20122 Milan, Italy
Interests: public health and epidemiology; infectious disease; surveillance and prepardness; vaccine and vaccination
Special Issues, Collections and Topics in MDPI journals
Dr. Benedicte Machiels

E-Mail Website
Guest Editor
Department of infectious and parasitic diseases, FARAH research centre, Faculty of Veterinary Medicine, University of Liege, 4000 Liege, Belgium
Interests: respiratory viruses; trained immunity; myeloid cell imprinting; immunopathologies; mucosal immunity

Special Issue Information

Dear Colleagues, 

In 2022, we will celebrate the 10th volume of the journal Vaccines (ISSN 2076-393X), and we would be happy if you join us on this wonderful occasion. 

/Vaccines/ is an international, peer-reviewed, quick-refereeing open access journal published online by MDPI, Basel, Switzerland. /Vaccines/ is indexed by SCIE, PubMed (NLM), etc. The Impact Factor is 4.422, ranking 74/162 (Q2) in Immunology, 63/140 (Q2) in Medicine, Research & Experimental in Pharmacology in Web of Science. The inaugural issue was released in 2013 and in 2020 we published the 1000th paper. In 2021, we have achieved the goal to publish 1200 papers in one year. The development of Vaccines is rapid. 

To mark this significant milestone, we are launching a Special Issue entitled “Vaccines: 10th Anniversary”. This Special Issue will include high-quality papers on topics within the broad scope of Vaccines. It is our pleasure to invite you to contribute an original research paper or a comprehensive review article on a trendy or hot topic for peer review and possible publication. 

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:

  • Vaccines against Infectious Diseases
  • Therapeutic Vaccines and Antibody Therapeutics
  • Cancer Vaccines and Immunotherapy
  • Influenza Virus/HIV/Veterinary/HPV/Hepatitis Virus Vaccines
  • Vaccines against (re)emerging and Tropical Infections Diseases
  • Innate and Adaptive Immunity in Vaccination/Clinical Immunology/Cellular/Molecular Immunology/Pathogens-host Immune Interface
  • Vaccines and Society/Epidemiology
  • Vaccine Adjuvants
  • Attenuated/Inactivated/Live and Vectored Vaccines/DNA and mRNA Vaccines
  • COVID-19 Vaccines and Vaccination
  • PK/PD (Pharmacokinetic/Pharmacodynamic Modeling) Approaches for Vaccination Optimization 

We look forward to receiving your contributions.

Prof. Dr. Fernando Ferreira
Dr. Amy Rasley
Dr. Domenico Mattoscio
Dr. Laura Pellegrinelli
Dr. Bénédicte Machiels
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (17 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2256 KiB  
Article
Competing Heterogeneities in Vaccine Effectiveness Estimation
by Ariel Nikas, Hasan Ahmed and Veronika I. Zarnitsyna
Vaccines 2023, 11(8), 1312; https://doi.org/10.3390/vaccines11081312 - 01 Aug 2023
Viewed by 914
Abstract
Understanding the waning of vaccine-induced protection is important for both immunology and public health. Population heterogeneities in underlying (pre-vaccination) susceptibility and vaccine response can cause measured vaccine effectiveness (mVE) to change over time, even in the absence of pathogen evolution and any actual [...] Read more.
Understanding the waning of vaccine-induced protection is important for both immunology and public health. Population heterogeneities in underlying (pre-vaccination) susceptibility and vaccine response can cause measured vaccine effectiveness (mVE) to change over time, even in the absence of pathogen evolution and any actual waning of immune responses. We use multi-scale agent-based models parameterized using epidemiological and immunological data, to investigate the effect of these heterogeneities on mVE as measured by the hazard ratio. Based on our previous work, we consider the waning of antibodies according to a power law and link it to protection in two ways: (1) motivated by correlates of risk data and (2) using a within-host model of stochastic viral extinction. The effect of the heterogeneities is given by concise and understandable formulas, one of which is essentially a generalization of Fisher’s fundamental theorem of natural selection to include higher derivatives. Heterogeneity in underlying susceptibility accelerates apparent waning, whereas heterogeneity in vaccine response slows down apparent waning. Our models suggest that heterogeneity in underlying susceptibility is likely to dominate. However, heterogeneity in vaccine response offsets <10% to >100% (median of 29%) of this effect in our simulations. Our study suggests heterogeneity is more likely to ‘bias’ mVE downwards towards the faster waning of immunity but a subtle bias in the opposite direction is also plausible. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

17 pages, 1613 KiB  
Article
A Case-Control Study on Factors of HPV Vaccination for Mother and Daughter in China
by Linyi Chen, Xihong Sun, Jing Luo, Yuanshan Zhang, Yu Ha, Xiaoxia Xu, Liandi Tao, Xuefeng Mu, Shengnan Gao, Yongchao Han, Chi Wang, Fuliang Wang, Juan Wang, Bingying Yang, Xiaoyan Guo, Yajie Yu, Xian Ma, Lijian Liu, Wenmin Ma, Pengmin Xie, Chao Wang, Guoxing Li, Qingbin Lu and Fuqiang Cuiadd Show full author list remove Hide full author list
Vaccines 2023, 11(5), 976; https://doi.org/10.3390/vaccines11050976 - 12 May 2023
Cited by 1 | Viewed by 1591
Abstract
(1) Background: To explore the influencing factors of human papillomavirus (HPV) vaccination among mothers and daughters so as to provide evidence and strategies for improving the HPV vaccination rate of 9–18-years-old girls. (2) A questionnaire survey was conducted among the mothers of 9–18-year-old [...] Read more.
(1) Background: To explore the influencing factors of human papillomavirus (HPV) vaccination among mothers and daughters so as to provide evidence and strategies for improving the HPV vaccination rate of 9–18-years-old girls. (2) A questionnaire survey was conducted among the mothers of 9–18-year-old girls from June to August 2022. The participants were divided into the mother and daughter vaccinated group (M1D1), the mother-only vaccinated group (M1D0), and the unvaccinated group (M0D0). Univariate tests, the logistic regression model, and the Health Belief Model (HBM) were employed to explore the influencing factors. (3) Results: A total of 3004 valid questionnaires were collected. According to the regions, Totally 102, 204, and 408 mothers and daughters were selected from the M1D1, M1D0, and M0D0 groups, respectively. The mother having given her daughter sex education (OR = 3.64; 95%CI 1.70, 7.80), the mother’s high perception of disease severity (OR = 1.79; 95%CI 1.02, 3.17), and the mother’s high level of trust in formal information (OR = 2.18; 95%CI 1.26, 3.78) were all protective factors for both the mother and her daughter’s vaccination. The mother’s rural residence (OR = 0.51; 95%CI 0.28, 0.92) was a risk factor for vaccination of both mother and daughter. The mother’s education of high school or above (OR = 2.12; 95%CI 1.06, 4.22), the mother’s high level of HPV and HPV vaccine knowledge (OR = 1.72; 95%CI 1.14, 2.58), and the mother’s high level of trust in formal information (OR = 1.72; 95%CI 1.15, 2.57) were protective factors of mother-only vaccination. The older the mother (OR = 0.95; 95%CI 0.91, 0.99) was classed as a risk factor for mother-only vaccination. “Waiting until the daughters are older to receive the 9-valent vaccine” is the main reason why the daughters of M1D0 and M0D0 are not vaccinated”. (4) Chinese mothers had a high willingness to vaccinate their daughters with the HPV vaccine. The higher education level of the mother, giving sex education to the daughter, the older ages of mothers and daughters, the mother’s high level of HPV and HPV vaccine knowledge, a high level of perception of the disease severity, and a high level of trust in formal information were promoting factors of HPV vaccination for mother and daughter, and rural residence was a risk factor to vaccination. To promote HPV vaccination in girls from 9–18 years old, communities could provide health education to rural mothers with low education levels; the government could advocate for HPV vaccination through issuing policy documents; and doctors and the CDC could popularize the optimal age for HPV vaccination to encourage mothers to vaccinate their daughters at the age of 9–14 years old. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

21 pages, 1233 KiB  
Article
The Polymorphic Membrane Protein G Has a Neutral Effect and the Plasmid Glycoprotein 3 an Antagonistic Effect on the Ability of the Major Outer Membrane Protein to Elicit Protective Immune Responses against a Chlamydia muridarum Respiratory Challenge
by Anatoli Slepenkin, Sukumar Pal, Steven Hoang-Phou, Abisola Abisoye-Ogunniyan, Amy Rasley, Patrik D’haeseleer, Matthew A. Coleman and Luis M. de la Maza
Vaccines 2023, 11(3), 504; https://doi.org/10.3390/vaccines11030504 - 21 Feb 2023
Cited by 1 | Viewed by 1467
Abstract
Chlamydia trachomatis is the most common bacterial sexually transmitted pathogen. The number of chlamydial infections continuous to increase and there is an urgent need for a safe and efficacious vaccine. To assess the ability of the Chlamydia muridarum polymorphic membrane protein G (PmpG) [...] Read more.
Chlamydia trachomatis is the most common bacterial sexually transmitted pathogen. The number of chlamydial infections continuous to increase and there is an urgent need for a safe and efficacious vaccine. To assess the ability of the Chlamydia muridarum polymorphic membrane protein G (PmpG) and the plasmid glycoprotein 3 (Pgp3) as single antigens, and in combination with the major outer-membrane protein (MOMP) to induce protection, BALB/c mice were immunized utilizing CpG-1826 and Montanide ISA 720 VG as adjuvants. Following vaccination with MOMP, significant humoral and cell-mediated immune responses were observed, while immunization with PmpG, or Pgp3, elicited weaker immune responses. Weaker immune responses were induced with MOMP+Pgp3 compared with MOMP alone. Following the intranasal challenge with C. muridarum, mice vaccinated with MOMP showed robust protection against body-weight loss, inflammatory responses in the lungs and number of Chlamydia recovered from the lungs. PmpG and Pgp3 elicited weaker protective responses. Mice immunized with MOMP+PmpG, were no better protected than animals vaccinated with MOMP only, while Pgp3 antagonized the protection elicited by MOMP. In conclusion, PmpG and Pgp3 elicited limited protective immune responses in mice against a respiratory challenge with C. muridarum and failed to enhance the protection induced by MOMP alone. The virulence of Pgp3 may result from its antagonistic effect on the immune protection induced by MOMP. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

18 pages, 1630 KiB  
Article
COVID-19 Incidence and Vaccine Effectiveness in University Staff, 1 March 2020–2 April 2022
by Luca Cegolon, Corrado Negro, Marco Pesce and Francesca Larese Filon
Vaccines 2023, 11(2), 483; https://doi.org/10.3390/vaccines11020483 - 19 Feb 2023
Cited by 4 | Viewed by 2616
Abstract
Background: University workers undergo intense social interactions due to frequent contact with students and colleagues and lectures in crowdy conditions. The aim of our study was to assess the incidence of COVID-19 infection and vaccine effectiveness in a cohort of workers of [...] Read more.
Background: University workers undergo intense social interactions due to frequent contact with students and colleagues and lectures in crowdy conditions. The aim of our study was to assess the incidence of COVID-19 infection and vaccine effectiveness in a cohort of workers of the University of Trieste from 1 March 2020 (start of the pandemic) through 2 April 2022. Methods: The University of Trieste implemented a number of public health policies to contain the spread of SARS-CoV-2 on the campus, including prompt contact tracing, enhanced ventilation of all premises, fomites disinfection and mandatory use of face masks indoors. In compliance with the surveillance protocol of the local public health department, university personnel were tested for SARS-CoV-2 by polymerase chain reaction (PCR) on a nasopharyngeal swab on demand, in the event of symptoms consistent with COVID-19 or for contact tracing, following close contact with a confirmed COVID-19 case. The incidence rates of SARS-CoV-2 infections were estimated as number of cases by number of person-days (p-d) at risk. Multivariable Cox proportional hazard regression model was employed to investigate the risk of primary COVID-19 infection, controlling for a number of potential confounders and expressing the risk as the adjusted hazard ratio (aHR) with a 95% confidence interval (95% CI). Results: The incidence of SARS-CoV-2 infection among university staff was lower than that of healthcare workers (HCWs) of the same area. Compared to unvaccinated colleagues (6.55 × 10,000 p-d), the raw incidence of SARS-CoV-2 infection was higher among university workers immunized with one (7.22 × 10,000 p-d) or two (7.48 × 10,000 p-d) doses of COVID-19 vaccines, decreasing in those receiving the booster (1.98 × 1000 p-d). The risk of infection increased only in postgraduate medical trainees (aHR = 2.16; 95% CI: 1.04; 4.48), though this was limited to the Omicron transmission period. After the implementation of the national vaccination campaign against COVID-19, workers immunized with the booster were less likely than unvaccinated workers to be infected by SARS-CoV-2 both before (aHR = 0.10; 95% CI: 0.06; 0.16) and after (aHR = 0.37; 95% CI: 0.27; 0.52) the Omicron transmission period. Vaccine effectiveness of the booster was 90% (=(1−0.10) × 100) before versus 63% (=(1−0.37) × 100) during the Omicron wave, without a significant difference between homologous (three doses of m-RNA vaccines) and heterologous immunization (first two doses of Vaxzevria followed by a third dose of m-RNA vaccine). Conclusions: The incidence of SARS-CoV-2 infection in university staff was lower than that of HCWs of ASUGI, likely because the testing-on-demand schedule inevitably missed the vast majority of asymptomatic infections. Therefore, the observed significantly protective effect of the booster dose in university personnel referred to symptomatic SARS-CoV-2 infections. The infection prevention and control policies implemented by the University of Trieste managed to equalize the biological risk between administrative and teaching staff. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

11 pages, 855 KiB  
Article
Using Dried Blood Spots for a Sero-Surveillance Study of Maternally Derived Antibody against Group B Streptococcus
by Erick Auma, Tom Hall, Simran Chopra, Sam Bilton, Laxmee Ramkhelawon, Fahimah Amini, Anna Calvert, Gayatri Amirthalingam, Christine E. Jones, Nick Andrews, Paul T. Heath and Kirsty Le Doare
Vaccines 2023, 11(2), 357; https://doi.org/10.3390/vaccines11020357 - 04 Feb 2023
Cited by 1 | Viewed by 1611
Abstract
Vaccination during pregnancy could protect women and their infants from invasive Group B Streptococcus (GBS) disease. To understand if neonatal dried blood spots (DBS) can be used to determine the amount of maternally derived antibody that protects infants against invasive GBS disease, a [...] Read more.
Vaccination during pregnancy could protect women and their infants from invasive Group B Streptococcus (GBS) disease. To understand if neonatal dried blood spots (DBS) can be used to determine the amount of maternally derived antibody that protects infants against invasive GBS disease, a retrospective case-control study was conducted in England between 1 April 2014 and 30 April 2015. The DBS of cases with invasive GBS disease (n = 61) were matched with healthy controls (n = 125). The haematocrit, DBS storage temperature, freeze-thaw cycle, and paired serum/DBS studies were set up to optimise the antibody assessment. The samples were analysed using a multiplex immunoassay, and the results were assessed using parametric and nonparametric tests. Antibody concentrations were stable at haematocrits of up to 50% but declined at 75%. DBS storage at room temperature was stable for three months compared with storage from collection at −20 °C and rapidly degraded thereafter. Total IgG levels measured in DBS and paired serum showed a good correlation (r2 = 0.99). However, due to suboptimal storage conditions, no difference was found in the GBS IgG levels between DBS samples from cases and controls. We have demonstrated a proof of concept that assays utilising DBS for assessing GBS serotype-specific antibodies in infants is viable. This method could be used to facilitate future large sero-correlate studies, but DBS samples must be stored at −20 °C for long term preservation of antibody. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

15 pages, 276 KiB  
Article
Investigate Non-EPI Vaccination Recommendation Practice from a Socio-Ecological Perspective: A Mixed-Methods Study in China
by Kaiyi Han, Zhiyuan Hou, Shiyi Tu, Qian Wang, Binbing Wang, Xiaoyu Liu, Shiqiang Jiang, Tracey Chantler and Heidi Larson
Vaccines 2022, 10(12), 2105; https://doi.org/10.3390/vaccines10122105 - 08 Dec 2022
Cited by 2 | Viewed by 1268
Abstract
The uptake of non-EPI vaccines, such as influenza and pneumonia vaccines, are very low in China compared to other countries. In China, immunization services are provided by dedicated vaccination service providers (VSPs), and their recommendation is the key to improve vaccine uptake. This [...] Read more.
The uptake of non-EPI vaccines, such as influenza and pneumonia vaccines, are very low in China compared to other countries. In China, immunization services are provided by dedicated vaccination service providers (VSPs), and their recommendation is the key to improve vaccine uptake. This study explores VSP recommendation practices for non-EPI vaccines from a socio-ecological perspective. A mixed-methods study, combining a questionnaire survey and key informant interviews, was conducted in Anhui, Shaanxi, and Guangdong provinces. 555 VSPs completed the valid questionnaire, and 49 VSPs participated in in-depth interviews. Among the surveyed VSPs, 51.54% stated that they always or often recommended non-EPI vaccines in work, and the remaining half reported that they sometimes or never recommended non-EPI vaccines. Most VSPs interviewed communicated about non-EPI vaccines with the public in an informed style, not a presumptive one, and provided the public with all the decision-making latitude. The infrequent recommendation of non-EPI vaccines was widely prevalent among Chinese VSPs regardless of their individual characteristics, and was mainly driven by the interpersonal relationship, institutional arrangement, and public policy. Firstly, the VSPs were concerned about conflicts arising from the recommendation of self-paid vaccines and the risk of adverse reactions following vaccination. Secondly, high workloads left them insufficient time to communicate about non-EPI vaccines. Thirdly, there was no performance assessment or financial incentive for VSPs to recommend non-EPI vaccination, and their main responsibility was around EPI vaccination. Therefore, multi-level socio-ecological systems around non-EPI vaccination should be improved to optimize the communication between VSPs and the public, which include a better system of legal redress to resolve potential misunderstandings between the VSPs and the public, more effective workload management through whole-process health information system and strengthening public health workforce, and the introduction of performance assessment and appropriate incentives on non-EPI vaccination. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
12 pages, 264 KiB  
Article
An O-Specific Polysaccharide/Tetanus Toxoid Conjugate Vaccine Induces Protection in Guinea Pigs against Virulent Challenge with Coxiella burnetii
by Stephen R. Graves, Aminul Islam, Lawrence D. Webb, Ian Marsh, Karren Plain, Mark Westman, Xavier A. Conlan, Rodney Carbis, Rudolf Toman and John Stenos
Vaccines 2022, 10(9), 1393; https://doi.org/10.3390/vaccines10091393 - 25 Aug 2022
Cited by 6 | Viewed by 1811
Abstract
Q fever is caused by the bacterium Coxiella burnetii and is spread to humans from infected animals especially goats, sheep and cattle, predominantly when giving birth. There is an effective human vaccine (Q-VAX) against Q fever, and although Q fever is a worldwide [...] Read more.
Q fever is caused by the bacterium Coxiella burnetii and is spread to humans from infected animals especially goats, sheep and cattle, predominantly when giving birth. There is an effective human vaccine (Q-VAX) against Q fever, and although Q fever is a worldwide problem, the vaccine is only used in Australia due to difficulties associated with its use and the risk of adverse reactions. The desire to protect humans, particularly farmers and abattoir workers, from Q fever prompted the development of a new safe and effective human vaccine without all the difficulties associated with the current vaccine. Candidate vaccines were prepared using purified O-specific polysaccharide (OSP) extracted from the lipopolysaccharide of virulent (phase 1) C. burnetii, strain Nine Mile, which was then conjugated to a tetanus toxoid (TT) carrier protein. Two vaccines were prepared using OSP from C. burnetii grown in embryonated eggs (vaccine A) and axenic media (vaccine B). Vaccines with or without alum adjuvant were used to vaccinate guinea pigs, which were later challenged by intranasal inoculation with virulent C. burnetii. Both vaccines protected guinea pigs from fever and loss of weight post challenge. Post-mortem samples of the spleen, liver and kidney of vaccinated guinea pigs contained substantially less C. burnetii DNA as measured by PCR than those of the unvaccinated control animals. This study demonstrated that a C. burnetii OSP-TT conjugate vaccine is capable of inducing protection against virulent C. burnetii in guinea pigs. Additionally, OSP derived from C. burnetii grown in axenic media compared to OSP from embryonated eggs is equivalent in terms of providing a protective immune response. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
7 pages, 203 KiB  
Article
COVID-19 Vaccine Hesitancy and Trust in Government in Nigeria
by Ryoko Sato
Vaccines 2022, 10(7), 1008; https://doi.org/10.3390/vaccines10071008 - 23 Jun 2022
Cited by 18 | Viewed by 2231
Abstract
Introduction: COVID-19 has been impacting our lives globally, including in Nigeria. While the COVID-19 vaccine is available free of charge, vaccination coverage remains low. This study evaluates the relationship between trust in government and COVID-19 vaccine hesitancy. Methods: We used an Afrobarometer survey [...] Read more.
Introduction: COVID-19 has been impacting our lives globally, including in Nigeria. While the COVID-19 vaccine is available free of charge, vaccination coverage remains low. This study evaluates the relationship between trust in government and COVID-19 vaccine hesitancy. Methods: We used an Afrobarometer survey for data on trust in government and the COVID-19 National Longitudinal Phone Survey (NLPS) for data on COVID-19 vaccine hesitancy, merged by strata (states and urban/rural). The simple correlation was evaluated using Ordinary Least Squares (OLS) regression. Results: Distrust in government was strongly associated with COVID-19 vaccine hesitancy as well as with perceptions that the vaccine was not safe, and concerns about side effects were given as reasons for vaccine refusal. Discussion/Conclusion: Distrust of government is an important predictor of vaccine hesitancy in Nigeria. This result is consistent with findings in the literature, especially in developed countries. Vaccine refusers, who distrust the government, refuse vaccines because they think that vaccines do them harm. Policy makers should be cautious when it comes to strategizing for COVID-19 vaccine distribution, especially in places where trust in government is weak. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
7 pages, 237 KiB  
Communication
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
by Chao Wang, Lin-Yi Chen, Qing-Bin Lu and Fuqiang Cui
Vaccines 2022, 10(6), 920; https://doi.org/10.3390/vaccines10060920 - 09 Jun 2022
Cited by 10 | Viewed by 2289
Abstract
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2) [...] Read more.
Vaccination against coronavirus disease 2019 (COVID-19) has become an important public health solution. Developing a safe and effective vaccine against COVID-19 is a viable long-term solution to control the pandemic. As one of the two inactivated severe acute respiratory syndrome virus 2 (SARS-CoV-2) vaccines developed in China that entered the WHO emergency use list, Sinopharm BBIBP-CorV, an aluminum-hydroxide-adjuvanted, inactivated whole-virus vaccine, has been widely distributed, with more than 400 million doses administered in more than 40 countries. The evidence of the safety, efficacy, and effectiveness of BBIBP-CorV is gathered and reviewed. We further comment on one of the latest papers that disclosed the effectiveness results between BBIBP-CorV, rAd26-rAd5, and ChAdOx1. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
10 pages, 1550 KiB  
Article
Live-Attenuated Oral Vaccines to Reduce Campylobacter Colonization in Poultry
by Byeonghwa Jeon, Tunchanok Saisom, Jiroj Sasipreeyajan and Taradon Luangtongkum
Vaccines 2022, 10(5), 685; https://doi.org/10.3390/vaccines10050685 - 27 Apr 2022
Cited by 8 | Viewed by 2484
Abstract
The control of Campylobacter in poultry at the pre-harvest level is critical to reducing foodborne infections with Campylobacter since the consumption of contaminated poultry is the most frequent cause of human campylobacteriosis. Although poultry vaccination is suggested as useful intervention measures, no Campylobacter [...] Read more.
The control of Campylobacter in poultry at the pre-harvest level is critical to reducing foodborne infections with Campylobacter since the consumption of contaminated poultry is the most frequent cause of human campylobacteriosis. Although poultry vaccination is suggested as useful intervention measures, no Campylobacter vaccines are currently available. To develop live-attenuated oral Campylobacter vaccines, in this study, we evaluated the efficacy of pre-colonization by oxidative stress defense mutants, including knockout mutants of ahpC, katA, and sodB, in preventing Campylobacter jejuni from colonizing poultry. Interestingly, when chickens were pre-colonized with ΔahpC and ΔkatA mutants, rather than the ΔsodB mutant, the level of C. jejuni colonization was significantly reduced within 35 days. Further studies demonstrated when chickens were pre-colonized with the ΔahpC mutant by oral challenge with a high dose (ca., 5 × 108 CFU/bird) and a low dose (ca., 5 × 106 CFU/bird), it twice reduced the level of C. jejuni by 3.9 log10CFU/g feces and 3 log10CFU/g feces after 42 days, respectively, compared to the untreated control. Due to a colonization defect, the ΔahpC mutant was removed from chickens within 42 days. After excretion from the host, moreover, the ΔahpC mutant cannot survive in aerobic environments because of compromised aerotolerance. Our findings suggest that the ahpC mutant has a great potential for on-farm application to control C. jejuni at the pre-harvest level. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

11 pages, 1412 KiB  
Article
Analysis of R848 as an Adjuvant to Improve Inactivated Influenza Vaccine Immunogenicity in Elderly Nonhuman Primates
by Kali F. Crofts, Beth C. Holbrook, Ralph B. D’Agostino, Jr. and Martha A. Alexander-Miller
Vaccines 2022, 10(4), 494; https://doi.org/10.3390/vaccines10040494 - 23 Mar 2022
Cited by 3 | Viewed by 2122
Abstract
Elderly individuals are highly susceptible to developing severe outcomes as a result of influenza A virus (IAV) infection. This can be attributed to alterations that span the aged immune system, which also result in reduced responsiveness to the seasonal inactivated vaccine. Given the [...] Read more.
Elderly individuals are highly susceptible to developing severe outcomes as a result of influenza A virus (IAV) infection. This can be attributed to alterations that span the aged immune system, which also result in reduced responsiveness to the seasonal inactivated vaccine. Given the rapidly increasing number of individuals in this age group, it is imperative that we develop strategies that can better protect this population from IAV-associated disease. Based on our previous findings that the TLR7/8 agonist resiquimod (R848) could efficiently boost responses in the newborn, another population with decreased vaccine responsiveness, we evaluated this adjuvant in an elderly African green monkey (AGM) model. AGM aged 16–24 years old (equivalent to 64–96 in human years) were primed and boosted with inactivated A/PuertoRico/8/1934 (H1N1) (IPR8) alone or directly linked to R848 (IPR8-R848). We observed increases in the level of circulating virus-specific IgM antibody 10 days following primary vaccination in AGM that were vaccinated with IPR8-R848, but not IPR8 alone. In addition, there were significant increases in virus-specific IgG after boosting selectively in the IPR8-R848 vaccinated animals. These findings provide insights into the ability of R848 to modulate the aged immune system in the context of IAV vaccination. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

11 pages, 2583 KiB  
Article
Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period
by Emanuele Amodio, Giuseppe Vella, Vincenzo Restivo, Alessandra Casuccio, Francesco Vitale and on behalf of the COVID-19 Surveillance Working Group of the University of Palermo
Vaccines 2022, 10(3), 426; https://doi.org/10.3390/vaccines10030426 - 11 Mar 2022
Cited by 8 | Viewed by 2323
Abstract
In order to reduce the spread of SARS-CoV-2 infection and the burden of disease, since 27 December 2020, Sicily has introduced a regional COVID-19 vaccination campaign. This study aimed at estimating the effectiveness of mRNA COVID-19 vaccines on SARS-CoV-2 infections and COVID-19. A [...] Read more.
In order to reduce the spread of SARS-CoV-2 infection and the burden of disease, since 27 December 2020, Sicily has introduced a regional COVID-19 vaccination campaign. This study aimed at estimating the effectiveness of mRNA COVID-19 vaccines on SARS-CoV-2 infections and COVID-19. A retrospective cohort study was carried out on 3,966,976 Sicilian adults aged 18 years or more, who were followed-up from 1 January 2021 to 30 September 2021. The risk of SARS-CoV-2 infection, severe COVID-19, and COVID-19 death or intubation during the study period was compared among vaccinated with two mRNA doses and unvaccinated individuals. Cox regression, adjusted for age and sex, and a joint-point analysis on rate trends were performed. Overall, 2,469,320 (62.2%) subjects have been vaccinated and a total of 103,078 (2.6% of the entire population) SARS-CoV-2-positive subjects have been observed including 4693 (0.12%) severe COVID-19, 277 (0.01%) intubated, and 2649 (0.07%) deaths. After two months from vaccination, adjusted vaccine effectiveness was 81.3% against SARS-CoV-2 infection, 96.1% against severe COVID-19, and 93.4% against intubation/death. During the eight-month follow-up, statistically significant decreasing effectiveness trends were observed for all the evaluated outcomes (−4.76% per month against SARS-CoV-2 infection; −2.27% per month against severe COVID-19 and −2.26% per month against COVID-19 intubation/death). The study results confirm that mRNA COVID-19 vaccines have high real-world effectiveness, especially in the first months after vaccination. The vaccine effectiveness decreases over time and, even if the decrease is relatively small against severe outcomes, the increasing protection wane suggests the need for booster vaccination campaigns. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

12 pages, 492 KiB  
Article
Adverse Reactions to Anti-SARS-CoV-2 Vaccine: A Prospective Cohort Study Based on an Active Surveillance System
by Emanuele Amodio, Giuseppa Minutolo, Alessandra Casuccio, Claudio Costantino, Giorgio Graziano, Walter Mazzucco, Alessia Pieri, Francesco Vitale, Maurizio Zarcone and Vincenzo Restivo
Vaccines 2022, 10(3), 345; https://doi.org/10.3390/vaccines10030345 - 23 Feb 2022
Cited by 13 | Viewed by 1803
Abstract
To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, [...] Read more.
To date, Coronavirus disease (COVID-19) has caused high morbidity and mortality worldwide. To counteract the pandemic scenario, several vaccines against the etiological factor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were developed and tested. At the end of December 2020, BNT162b2 (Comirnaty, Pfizer-BioNTech) was the first and only authorized vaccine in Italy for selected categories, such as healthcare workers, fragile patients and people aged over 80 years old. To master our knowledge about BNT162b2 adverse reactions (ARs), an active surveillance system based on instant messaging was realized for voluntary participants who had been vaccinated at COVID-19 Vaccination Center of the Palermo University Hospital. Overall, 293 vaccinated persons were included in this study, which were more frequently healthcare workers (n = 207, 70.6% with a median age of 36 years, IQR = 29–55) followed by health professional students (n = 31, 10.6% with a median age of 27 years, IQR = 25–29), reporting 82.6% of at least one local or systemic AR. In details, the frequency of at least one local or systemic AR after the second dose of Comirnaty (n = 235, 80.2%) was statistically significant with higher value in comparison to the first one (n = 149, 50.9%; p < 0.001). However, local pain, swelling, joint pain and muscular pain after the second dose were the symptom causing a statistically significant working limitation. The youngest persons showed a higher risk to have either local or systemic ARs (aOR = 7.5, CI 95% = 2.9–18.9), while females had a higher risk of having systemic ARs (aOR = 1.8, CI 95% = 1.1–3.0). Despite the small sample examined, this active surveillance system by instant messaging seems to detect a higher ARs prevalence with respect to data obtained by the passive surveillance. Further studies could be required in order to optimize this clinical monitoring that could be considered an efficient and timely active surveillance. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

8 pages, 965 KiB  
Article
Evaluation and Validation of the Roche Elecsys SARS-CoV-2 Antigen Electro-Chemiluminescent Immunoassay in a Southeast Asian Region
by Chin Shern Lau, Soon Kieng Phua, See Ping Hoo, Boran Jiang and Tar-Choon Aw
Vaccines 2022, 10(2), 198; https://doi.org/10.3390/vaccines10020198 - 27 Jan 2022
Cited by 5 | Viewed by 2449
Abstract
Introduction: SARS-CoV-2 antigen tests can complement and substitute for RT-PCR tests. Centralized laboratory automated SARS-CoV-2 antigen tests that can be scaled to process a large number COVID-19 cases simultaneously are now available. We have evaluated the new Roche Elecsys SARS-CoV-2 antigen electro-chemiluminescent immunoassay. [...] Read more.
Introduction: SARS-CoV-2 antigen tests can complement and substitute for RT-PCR tests. Centralized laboratory automated SARS-CoV-2 antigen tests that can be scaled to process a large number COVID-19 cases simultaneously are now available. We have evaluated the new Roche Elecsys SARS-CoV-2 antigen electro-chemiluminescent immunoassay. Methods: The Roche SARS-CoV-2 antigen assay is a double-antibody sandwich electro-chemiluminescent immunoassay, which reports a cut-off index (COI) (COI ≥ 1.0 considered positive). We assessed assay precision and linearity, and confirmed the reactivity limit. We determined the assay sensitivity and specificity with a verification group (289 controls and 61 RT-PCR positive COVID-19 cases). Assay performance was also validated against the consecutive samples we received (7657 controls and 17 cases) for SARS-CoV-2 antigen testing from June to October 2021. Result: The assay had a within-run precision CV of 3.0% at COI 0.68, and a CV of 1.5% at COI 3.49. Between-run precision was 3.0% at COI 0.68 and 1.8% at COI 3.49. The assay was linear from COI 0.65 to 7.84. All 35 C50 ± 20% test results performed over 7 days were positive/negative, respectively. In the verification group, overall sensitivity was 42.6% (26/61 positive, 95% CI 30.0–55.9), and specificity was 99.7% (1/289 positive, 95% CI 98.1–100). The agreement between the SARS-CoV-2 antigen and the RT-PCR cycle threshold (Ct) count was good (r = 0.90). In cases with Ct counts ≤ 30, the antigen assay sensitivity improved to 94.7% (18/19 positive, 95% CI 74.0–99.9). In our validation group, antigen sensitivity was 62.5% (5/8 antigen positive, 95% CI 24.5–91.5) within the first week of disease onset, but no cases were reactive after the first week of disease onset. Conclusion: The Elecsys SARS-CoV-2 antigen assay has good performance within manufacturer specifications. The sensitivity of the Roche antigen assay was greatest when used in patients with lower RT-PCR Ct values (≤30) and within the first week of disease onset. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

Review

Jump to: Research

15 pages, 719 KiB  
Review
Understanding Diversity of Policies, Functionalities, and Operationalization of Immunization Information Systems and Their Impact: A Targeted Review of the Literature
by Elizabeth A. Donckels, Luke Cunniff, Nina Regenold, Kaitlyn Esselman, Erik Muther, Alexandra Bhatti and Amanda L. Eiden
Vaccines 2023, 11(7), 1242; https://doi.org/10.3390/vaccines11071242 - 15 Jul 2023
Cited by 1 | Viewed by 1565
Abstract
The COVID-19 pandemic has focused attention on the use of immunization information systems (IIS) to record and consolidate immunization records from a variety of sources to generate comprehensive patient immunization histories. Operationalization of IIS in the United States is decentralized, and as such, [...] Read more.
The COVID-19 pandemic has focused attention on the use of immunization information systems (IIS) to record and consolidate immunization records from a variety of sources to generate comprehensive patient immunization histories. Operationalization of IIS in the United States is decentralized, and as such, there are over 60 different IIS with wide variations in enabling policies and functionalities. As such, the policies that inform the development and operation of those sub-national IIS exist at the state and sometimes city levels. A targeted literature review was conducted to identify IIS policies and functionalities and assess their impact. The authors identified articles published from 2012 to 2022 that discussed or evaluated IIS policies and functionalities and screened titles, abstracts, and full text for inclusion. When selected for inclusion, authors extracted IIS policy/functionality characteristics and qualitative or quantitative outcomes of their implementation, where applicable. The search terms yielded 86 articles, of which 39 were included in the analysis. The articles were heterogeneous with respect to study design, interventions, outcomes, and effect measures. Out of the 17 IIS policies and functional components identified in the targeted literature review, the most commonly evaluated were provider-based patient reminder/recall, IIS-based centralized reminder/recall, and clinical decision support. Patient reminder/recall had the most published research and was associated with increased vaccination rates and vaccine knowledge. Despite the lack of quantitative evidence, there is a consensus that immunization data interoperability is critical to supporting IIS data quality, access, and exchange. Significant evidence gaps remain about the effectiveness of IIS functionalities and policies. Future research should evaluate the impact of policies and functionalities to guide improved utilization of IIS, increase national interoperability and standardization, and ultimately improve vaccination coverage and population health. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

13 pages, 5370 KiB  
Review
Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers
by Hongyu Zhang, Zhenyu Wu, Deyu Hu, Min Yan, Jing Sun, Jiejuan Lai and Lianhua Bai
Vaccines 2022, 10(7), 1023; https://doi.org/10.3390/vaccines10071023 - 26 Jun 2022
Cited by 2 | Viewed by 2778
Abstract
Neuro-glia antigen 2/chondroitin sulfate proteoglycan 4 (NG2/CSPG4, also called MCSP, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a large cell-surface antigen and an unusual cell membrane integral glycoprotein frequently expressed on undifferentiated precursor cells in multiple solid organ cancers, including cancers of the [...] Read more.
Neuro-glia antigen 2/chondroitin sulfate proteoglycan 4 (NG2/CSPG4, also called MCSP, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) is a large cell-surface antigen and an unusual cell membrane integral glycoprotein frequently expressed on undifferentiated precursor cells in multiple solid organ cancers, including cancers of the liver, pancreas, lungs, and kidneys. It is a valuable molecule involved in cancer cell adhesion, invasion, spreading, angiogenesis, complement inhibition, and signaling. Although the biological significance underlying NG2/CSPG4 proteoglycan involvement in cancer progression needs to be better defined, based on the current evidence, NG2/CSPG4+ cells, such as pericytes (PCs, NG2+/CD146+/PDGFR-β+) and cancer stem cells (CSCs), are closely associated with the liver malignancy, hepatocellular carcinoma (HCC), pancreatic malignancy, and pancreatic ductal adenocarcinoma (PDAC) as well as poor prognoses. Importantly, with a unique method, we successfully purified NG2/CSPG4-expressing cells from human HCC and PDAC vasculature tissue blocks (by core needle biopsy). The cells appeared to be spheres that stably expanded in cultures. As such, these cells have the potential to be used as sources of target antigens. Herein, we provide new information on the possibilities of frequently selecting NG2/CSPG4 as a solid organ cancer biomarker or exploiting expressing cells such as CSCs, or the PG/chondroitin sulfate chain of NG2/CSPG4 on the cell membrane as specific antigens for the development of antibody- and vaccine-based immunotherapeutic approaches to treat these cancers. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

16 pages, 6292 KiB  
Review
Leveraging Beneficial Off-Target Effects of Live-Attenuated Rotavirus Vaccines
by Prisca Benedicto-Matambo, Julie E. Bines, Chikondi Malamba-Banda, Isaac T. Shawa, Kayla Barnes, Arox W. Kamng’ona, Daniel Hungerford, Kondwani C. Jambo, Miren Iturriza-Gomara, Nigel A. Cunliffe, Katie L. Flanagan and Khuzwayo C. Jere
Vaccines 2022, 10(3), 418; https://doi.org/10.3390/vaccines10030418 - 10 Mar 2022
Cited by 4 | Viewed by 4165
Abstract
Following the introduction of live-attenuated rotavirus vaccines in many countries, a notable reduction in deaths and hospitalisations associated with diarrhoea in children <5 years of age has been reported. There is growing evidence to suggest that live-attenuated vaccines also provide protection against other [...] Read more.
Following the introduction of live-attenuated rotavirus vaccines in many countries, a notable reduction in deaths and hospitalisations associated with diarrhoea in children <5 years of age has been reported. There is growing evidence to suggest that live-attenuated vaccines also provide protection against other infections beyond the vaccine-targeted pathogens. These so called off-target effects of vaccination have been associated with the tuberculosis vaccine Bacille Calmette Guérin (BCG), measles, oral polio and recently salmonella vaccines, and are thought to be mediated by modified innate and possibly adaptive immunity. Indeed, rotavirus vaccines have been reported to provide greater than expected reductions in acute gastroenteritis caused by other enteropathogens, that have mostly been attributed to herd protection and prior underestimation of rotavirus disease. Whether rotavirus vaccines also alter the immune system to reduce non targeted gastrointestinal infections has not been studied directly. Here we review the current understanding of the mechanisms underlying off-target effects of vaccines and propose a mechanism by which the live-attenuated neonatal rotavirus vaccine, RV3-BB, could promote protection beyond the targeted pathogen. Finally, we consider how vaccine developers may leverage these properties to improve health outcomes in children, particularly those in low-income countries where disease burden and mortality is disproportionately high relative to developed countries. Full article
(This article belongs to the Special Issue Vaccines: 10th Anniversary)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-17
Back to TopTop